22 BOSTON WHARF ROAD, BOSTON, MA
Interim CFO Appointment - Kameel Farag Named Chief Financial Officer
Akari Therapeutics Enters Into Securities Purchase Agreement for ADSs
Akari Therapeutics Announces $2.5 Million Registered Direct Offering
Other Events
News, Material Contracts
Investor Presentation
Q1
FY 2024
Notice of Late Filing for Annual Report
Q3
Notice of Late Filing for Quarterly Report
Q2
Notice of Exempt Offering of Securities
Prospectus filed pursuant to Rule 424(b)(5)
S-1
Effectiveness Notice
Registration Statement for Securities to be Offered to Employees
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Correspondence
Submission Upload
Post-Effective Amendment to Registration Statement
Post-Effective Amendment to a Registration Statement for Depositary Shares